D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
87,300
+2,400 (2.83%)
Dec 10, 2025, 3:30 PM KST
777.39%
Market Cap3.69T
Revenue (ttm)8.36B
Net Income (ttm)-34.76B
Shares Out43.43M
EPS (ttm)-845.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,671,815
Average Volume1,689,383
Open84,100
Previous Close84,900
Day's Range80,500 - 89,300
52-Week Range10,125 - 113,700
Betan/a
RSI52.67
Earnings DateNov 14, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.